Navigation Links
Luxcel Biosciences and HD Biosciences Enter Collaboration Agreement for Mitochondria Toxicity & Metabolism Assays for Preclinical Drug Safety Evaluation

CORK, Ireland and SHANGHAI, March 1, 2017 /PRNewswire/ -- Luxcel Biosciences Ltd (Luxcel), a Cork based Biotechnology Company and HD Biosciences Co., Ltd. (HDB), a leading preclinical drug discovery Contract Research Organization (CRO), announced today that they have entered a strategic partnership to co-market and provide new assay technologies for preclinical drug safety services. Under the agreement, HDB will gain access to Luxcel's state-of-the-art assays and technologies for assessment of mitochondrial function, toxicity and metabolism.

Mitochondrial dysfunction is a major contributor to drug-induced toxicity, post-market drug withdrawal and black box warnings for hepatic and cardiac toxicity. A major focus of the collaboration is the Respirometric Screening Technology (RST/OCR) assay, originally developed by Luxcel in collaboration with Pfizer Inc. (Ref: Will, Y et al (2006) Nature Protocols). A significant advance of the RST assay, versus the commonly used Glu/Gal assay, is its ability to accurately differentiate specific mitochondrial toxicity from non-specific toxicity, as well as un-couplers of mitochondrial function from inhibitors. The RST assay is fully validated in high throughput format and in weekly production mode at HDB, Shanghai, providing clients with the best mitochondrial toxicity assay available with cost effective and quick turnaround service.

RST Assay
RST Assay

"We are delighted to team up with Luxcel Biosciences Ltd, a leader in the field of optical sensing technologies." "HDB offers a full range of in vitro toxicology services including safety profiling panels (Safety Assess™), as well as cardiotoxicity, hepatotoxicity, genotoxicity and cytotoxicity screenings. Luxcel's growing portfolio of proprietary mitochondria toxicity, bioenergetics & metabolism assays, is highly complementary to our current offerings and provides early and effective identification of mitochondrial liabilities for our client's drug discovery programs," stated Dr. Peiyuan Lin, Senior VP of R&D Services of HDB.

"HDB has established and maintained a professional reputation globally with its pre-clinical service, bringing their clients the most up to date and valuable assays and tools to advance the drug discovery process. This joint effort will leverage the extensive expertise and capabilities from both sides, for the benefit of global as well as China-based pharmaceutical and biotech companies," said Dr. Ian Hayes, Commercial Director for Luxcel.

Contact Alanna Carty +353 86 2741539

About Luxcel Biosciences Ltd

Luxcel Biosciences was founded in 2002 in Co. Cork, Ireland, and is a multi-award winning provider of cost effective and easy to use fluorescence-based in vitro cell test kits, targeting cell metabolism, bioenergetics and drug toxicity applications.  Customers range from University research scientists, to global Pharmaceutical Companies and Contract Research Organisations.  Pfizer Inc., one of the world's largest pharmaceutical companies, is a key collaborator in the field of drug safety and mitochondrial toxicity screening. Several joint research publications in high impact journals have resulted from this successful collaboration.

About HD Biosciences

HD Biosciences Co., Ltd. is a biology-focused preclinical drug discovery contract research organization (CRO) with headquarter in Shanghai, and operation facilities in Beijing and San Diego, USA. The company offers comprehensive research and development services to global pharmaceutical and biotech industries around target validation, plate-based pharmacology, hit identification & lead discovery, therapeutic antibody discovery, in vivo pharmacology, and other related areas. The company currently collaborates with eight (8) of the ten (10) largest pharmaceutical companies in the world and has established strategic partnerships with impacts to their portfolios. The strong scientific expertise, high quality of the services, consistency in deliveries, and constantly meeting or exceeding expectations, have helped the company to earn an excellent reputation in the industry. The in vitro pharmacology R&D and other core competencies of the company are widely recognized as one of the best among preclinical CROs.

About RST/OCA Assay

Please visit:

To view the original version on PR Newswire, visit:

SOURCE Luxcel Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. ACEA Biosciences Hires Roger Luo as Vice President of Global Clinical Development
2. Research Reports Coverage on Biotech Stocks -- Anthera Pharma, Arrowhead Pharma, Pacific Biosciences of California, and Conatus Pharma
3. Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
4. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
5. Caprion Biosciences wird Kurzlehrgang und Poster bei Molecular Medicine Tri-Conference in San Francisco präsentieren
6. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
7. Swift Biosciences Expands Team, Hires Vice President of Marketing
8. ACEA Biosciences Announces Winners of its Travel Award
9. WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences
10. Vigilant Biosciences to Present at Medtech Showcase 2017 and BioLink 2017 China Healthcare Industry Investment and Licensing Conference
11. Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Surgical Wound Market with the addition of its newest module, US Hemostats & ... market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at . 2016 Year ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):